Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes and CKD

What is it about?

People with type 1 diabetes are at increased risk of developing worsening kidney disease. There are currently few therapies to treat kidney disease in type 1 diabetes. SGLT inhibitors protect kidney function in patients with type 2 diabetes, though these benefits have not been demonstrated in type 1 diabetes. In a group of people with type 1 diabetes and kidney disease studied in the inTandem clinical trials, the SGLT inhibitor sotagliflozin improved blood sugar control, body weight and blood pressure, all factors associated with kidney protection. This was safe, without an increased risk of severely low blood sugars. The risk of diabetic ketoacidosis, a known complication of SGLT inhibitors, especially in people with type 1 diabetes, was not increased among those with type 1 diabetes and kidney disease compared to people without kidney disease.

Featured Image